Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bard launches three-minute bladder cancer test

This article was originally published in Clinica

Executive Summary

Bard has launched a three-minute test for bladder cancer. Bard BTA, a latex agglutination and test strip assay, was introduced at the European Urological Winter Forum at Davos, Switzerland. Bard says the kit greatly improves on the noninvasive standard, voided urine cytology (VUC). An unpublished US study is reported to have found BTA to be nine times more sensitive than VUC in detecting Ta (superficial) grade I/II tumours and two and a half times as sensitive in Ta grade III and T1 (invasive) grade II/III tumours. In the case of flat tumours both methods performed equally well. Sensitivity of the new test is 96%.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT090592

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel